5.0 on Google

← Back to Research Hub

GHK-Cu: Published Research, Chemical Identity and Batch Documentation

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, which was isolated from human plasma. In fibroblast cultures it stimulated collagen synthesis at nanomolar concentrations, and rat wound-model studies report extracellular-matrix changes alongside at least one null result. Vial & Error supplies GHK-Cu

Vial & Error identity card for GHK-Cu, the copper(II) complex of Gly-His-Lys
GHK-Cu identity card: the copper(II) complex of glycyl-L-histidyl-L-lysine (PubChem CID 71587328).

Batch documentation

The 98%+ purity floor applies to GHK-Cu as it does to every compound we list, and it is verified twice: by the manufacturer COA and by independent analysis at ACS Peptide Testing Labs. The ACS entry for this batch is below.

Batch testedVe2026-chic-001
LaboratoryACS Peptide Testing Labs
Accession numberAAHV643
Purity (LCMS-UV)99.94%
Mass identificationGHK-Cu
ReportedJuly 28, 2026

These numbers are specific to the one sample ACS tested. View the COA and ACS report on the GHK-Cu product page.

What is GHK-Cu? Chemical identity

SequenceGly-His-Lys, copper(II) complex [1]
CAS number89030-95-5 (prezatide copper) [PubChem]
Molecular formulaC14H23CuN6O4+ (as listed by PubChem) [PubChem]
Molecular weight402.92 g/mol (computed, PubChem) [PubChem]
PubChem CID71587328 [PubChem]

Identity values from PubChem CID 71587328. A salt form such as acetate has a higher molecular weight than the value above; defer to the batch COA.

What have published studies on GHK-Cu examined?

About these rows: they include a null result and a finding that did not persist, so they are not a uniform list of positive effects. All are animal or in-vitro experiments, with conditions quoted as published for literature reference only, not as guidance, recommendations or protocols for any use.

Published GHK-Cu study conditions in non-human models and in-vitro systems
Model typeModelConcentration or dose (as reported)RouteDurationOutcome (as reported)Source
In vitroFibroblast culturesEffect began at 10⁻¹²–10⁻¹¹ M, maximal at 10⁻⁹ M (as reported)Culture mediumNot stated in abstractIncreased collagen synthesis, independent of cell numberMaquart FX 1988 [1]
PMID 3169264 · DOI
AnimalRat subcutaneous wound chamberVarious concentrations (not stated in abstract)Injection into wound chamberNot stated in abstractConcentration-dependent increases in dry weight, DNA, protein, collagen and glycosaminoglycans; type I and III collagen mRNA up; control tripeptide had no effectMaquart FX 1993 [2]
PMID 8227353 · DOI
Animal + in vitroRat wound chamber; rat dermal fibroblasts2 mg per injection (as reported)Injection into wound chamber; culture mediumUp to day 22Increased type I collagen and glycosaminoglycans; decorin mRNA up and biglycan mRNA downSiméon A 2000 [3]
PMID 11121126 · DOI
In vitroDermal fibroblast culturesNot stated in abstractCulture mediumNot stated in abstractIncreased MMP-2 protein and mRNA, and TIMP-1 and TIMP-2 secretion; copper ions alone reproduced the MMP-2 effect, GHK alone did notSiméon A 2000 [4]
PMID 11045606 · DOI
AnimalRat, ischemic open wounds (n = 24)2% gel (as reported)Topical, daily13 daysWound area reduced 64.5% vs 45.6% (vehicle) and 28.2% (control) by day 13; lower TNF-α, MMP-2 and MMP-9Canapp SO Jr 2003 [5]
PMID 14648529 · DOI
AnimalRat, ACL reconstruction (n = 72)0.3 or 3 mg/mL (as reported)Intra-articular, weekly from week 24 weekly injections; assessed at 6 and 12 weeksSmaller knee-laxity difference and higher stiffness (0.3 mg/mL) at 6 weeks; no differences at 12 weeks; no differences in ultimate load, gait or histologyFu SC 2015 [6]
PMID 25731775 · DOI
AnimalIrradiated rat dorsal skin flapsNot stated in abstractTopical gel, twice daily10 daysNo difference vs control in flap ischemia, vessel number or area, or VEGF expression (null result)Parker NP 2013 [7]
PMID 23744835 · DOI
In vitro (human-derived cells)Primary human dermal fibroblasts, normal and irradiated, in culture1 × 10⁻⁹ mol/L (as reported)Serum-free culture mediumNot stated in abstractFaster population doubling; irradiated cells produced more bFGF and VEGF early after exposurePollard JD 2005 [8]
PMID 15655171 · DOI

Anecdotal or calculation only. Not dosing guidance or medical advice. For laboratory research use only.

Every entry draws on the PubMed abstract. A cell marked "Not stated in abstract" means the number sits in the paper’s full text, which we did not transcribe.

What mechanisms have been reported for GHK-Cu?

The first point is background on the peptide; the rest are cell-culture and rat findings from the cited sources, ending with a model where no effect was seen.

  • GHK is a tripeptide with an affinity for copper(II) ions that was isolated from human plasma, and a GHK sequence occurs in the α2(I) chain of type I collagen. [1]
  • In rat wound chambers and dermal fibroblast cultures, GHK-Cu increased decorin mRNA and decreased biglycan mRNA. [3]
  • In fibroblast cultures, GHK-Cu increased MMP-2 expression together with TIMP-1 and TIMP-2 secretion; copper ions alone reproduced the MMP-2 effect but GHK alone did not. [4]
  • Not every model shows an effect: in irradiated rat skin flaps, topical GHK-Cu gel produced no difference from control. [7]

Handling and storage of GHK-Cu (supplier guidance)

Supplier guidance pending confirmation: desiccated at −20 °C for the long term and 2–8 °C for the short term, shielded from light and moisture. Bring the vial to room temperature before opening to limit condensation.

No GHK-Cu stability data are cited here, and nothing on this page establishes how long a reconstituted solution remains usable. Defer to your laboratory’s own validated methods.

Why researchers source GHK-Cu from Vial & Error

  • A published ACS Peptide Testing Labs report is on file.
  • Held to a 98%+ purity floor, with the manufacturer COA and the ACS result both on record.
  • The literature table includes studies that found no lasting effect, each linked by PMID or DOI.

Add GHK-Cu to your research order

The GHK-Cu product page holds the COA section for the batch tabulated above, plus ordering.

See GHK-Cu specifications and order Jump to checkout with GHK-Cu

Reading across compounds? The BPC-157 ACS batch report sits on its own page.

Frequently asked questions

What is GHK-Cu?

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. PubChem lists prezatide copper (CAS 89030-95-5, CID 71587328) as C14H23CuN6O4+ with a computed molecular weight of 402.92 g/mol.

What models has GHK-Cu been studied in?

The studies in our table used fibroblast cultures (including primary human-derived fibroblasts in vitro) and rat wound, skin-flap and ligament-reconstruction models. Every row is tagged as animal or in vitro.

Do all GHK-Cu studies report an effect?

No. A 2013 irradiated rat skin-flap study found no difference from control, and a 2015 rat ACL study found effects at 6 weeks that were gone by 12 weeks. Both are in our table.

Which GHK-Cu batch was tested by ACS Peptide Testing Labs?

The current ACS Peptide Testing Labs report lists purity by LCMS-UV and mass identification for the sample tested. These numbers are specific to the one sample ACS tested.

How should lyophilized GHK-Cu be stored?

Per supplier guidance (still unconfirmed by manufacturer stability data), keep it desiccated at −20 °C for the long term or 2–8 °C for the short term, away from light and moisture.

Does the GHK-Cu table recommend concentrations?

No. The table records published fibroblast-culture and rat-model conditions as a literature reference, not as guidance for any use. GHK-Cu from Vial & Error is

References

  1. Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988. PMID 3169264 · doi:10.1016/0014-5793(88)80509-x
  2. Maquart FX, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993. PMID 8227353 · doi:10.1172/JCI116842
  3. Siméon A, et al. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 2000. PMID 11121126 · doi:10.1046/j.1523-1747.2000.00166.x
  4. Siméon A, et al. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000. PMID 11045606 · doi:10.1016/s0024-3205(00)00803-1
  5. Canapp SO Jr, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg. 2003. PMID 14648529 · doi:10.1111/j.1532-950x.2003.00515.x
  6. Fu SC, et al. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res. 2015. PMID 25731775 · doi:10.1002/jor.22831
  7. Parker NP, et al. Effects of topical copper tripeptide complex on wound healing in an irradiated rat model. Otolaryngol Head Neck Surg. 2013. PMID 23744835 · doi:10.1177/0194599813492644
  8. Pollard JD, et al. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg. 2005. PMID 15655171 · doi:10.1001/archfaci.7.1.27

[PubChem] National Center for Biotechnology Information. PubChem Compound Summary, CID 71587328.

Prepared by Vial & Error Labs LLC. Last updated November 16, 2026.

Research Use Only. Not for human or veterinary consumption.

Ask Kim
Vial & Error Labs LLC
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.